KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed EBITDA Margin for 4 consecutive years, with 549.32% as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, EBITDA Margin rose 43157.0% year-over-year to 549.32%, compared with a TTM value of 410.13% through Dec 2023, up 3831.0%, and an annual FY2024 reading of 585445.74%, down 37020264.0% over the prior year.
  • EBITDA Margin was 549.32% for Q3 2023 at Ginkgo Bioworks Holdings, down from 214.73% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 9472.54% in Q4 2020 and bottomed at 1171.34% in Q4 2021.
  • Average EBITDA Margin over 4 years is 373.01%, with a median of 252.72% recorded in 2023.
  • The sharpest move saw EBITDA Margin crashed -1064388bps in 2021, then surged 100061bps in 2022.
  • Year by year, EBITDA Margin stood at 9472.54% in 2020, then plummeted by -112bps to 1171.34% in 2021, then soared by 85bps to 170.73% in 2022, then plummeted by -222bps to 549.32% in 2023.
  • Business Quant data shows EBITDA Margin for DNA at 549.32% in Q3 2023, 214.73% in Q2 2023, and 252.72% in Q1 2023.